SPOTLIGHT -
FDA Approves Drug Combo for Young Glioma Patients
A combination of dabrafenib with trametinib was approved by the FDA for treatment of pediatric patients 1 year and older with low-grade glioma & BRAF V600E mutation who require systemic therapy.
